Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,678 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.
Morgan RJ, Synold T, Mamelak A, Lim D, Al-Kadhimi Z, Twardowski P, Leong L, Chow W, Margolin K, Shibata S, Somlo G, Yen Y, Frankel P, Doroshow JH. Morgan RJ, et al. Among authors: yen y. Cancer Chemother Pharmacol. 2010 Oct;66(5):927-33. doi: 10.1007/s00280-010-1242-z. Epub 2010 Jan 28. Cancer Chemother Pharmacol. 2010. PMID: 20107803 Free PMC article. Clinical Trial.
Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial.
Yen Y, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Twardowski P, Frankel P, Longmate J, Synold T, Newman EM, Lenz HJ, Gandara D, Doroshow JH. Yen Y, et al. Cancer Chemother Pharmacol. 2002 Nov;50(5):353-9. doi: 10.1007/s00280-002-0492-9. Epub 2002 Sep 12. Cancer Chemother Pharmacol. 2002. PMID: 12439592 Clinical Trial.
Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies.
Morgan RJ Jr, Newman EM, Sowers L, Scanlon K, Harrison J, Akman S, Leong L, Margolin K, Niland J, Raschko J, Somlo G, Carroll M, Chow W, Tetef M, Hamasaki V, Yen Y, Doroshow JH. Morgan RJ Jr, et al. Among authors: yen y. Cancer Chemother Pharmacol. 2003 Jun;51(6):459-64. doi: 10.1007/s00280-003-0605-0. Epub 2003 Apr 15. Cancer Chemother Pharmacol. 2003. PMID: 12695856 Clinical Trial.
Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
Morgan RJ Jr, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, Stalter S. Morgan RJ Jr, et al. Among authors: yen y. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5896-901. Clin Cancer Res. 2003. PMID: 14676112 Clinical Trial.
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Chow WA, Synold TW, Tetef ML, Longmate J, Frankel P, Lawrence J, Al-Khadimi Z, Leong L, Lim D, Margolin K, Morgan RJ Jr, Raschko J, Shibata S, Somlo G, Twardowski P, Yen Y, Doroshow JH. Chow WA, et al. Among authors: yen y. Cancer Chemother Pharmacol. 2004 Sep;54(3):241-8. doi: 10.1007/s00280-004-0803-4. Epub 2004 Jun 2. Cancer Chemother Pharmacol. 2004. PMID: 15173955 Clinical Trial.
Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer.
Morgan RJ Jr, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH. Morgan RJ Jr, et al. Among authors: yen y. Cancer Chemother Pharmacol. 2004 Oct;54(4):283-9. doi: 10.1007/s00280-004-0818-x. Epub 2004 Jun 4. Cancer Chemother Pharmacol. 2004. PMID: 15184995 Clinical Trial.
Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
Margolin KA, Doroshow JH, Frankel P, Chow W, Leong LA, Lim D, McNamara M, Morgan RJ, Shibata S, Somlo G, Twardowski P, Yen Y, Kogut N, Schriber J, Alvarnas J, Stalter S. Margolin KA, et al. Among authors: yen y. Biol Blood Marrow Transplant. 2005 Nov;11(11):903-11. doi: 10.1016/j.bbmt.2005.07.010. Biol Blood Marrow Transplant. 2005. PMID: 16275593 Free article. Clinical Trial.
A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression.
Shibata S, Chow W, Frankel P, Juhasz A, Leong L, Lim D, Margolin K, Morgan R, Newman E, Somlo G, Yen Y, Synold T, Gandara D, Lenz HJ, Doroshow J. Shibata S, et al. Among authors: yen y. Cancer Chemother Pharmacol. 2007 Mar;59(4):549-57. doi: 10.1007/s00280-006-0297-3. Epub 2006 Oct 19. Cancer Chemother Pharmacol. 2007. PMID: 17051371 Clinical Trial.
Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
Morgan RJ Jr, Synold TW, Xi B, Lim D, Shibata S, Margolin K, Schwarz RE, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Tetef M, Lin P, Paz B, Koczywas M, Wagman L, Chu D, Frankel P, Stalter S, Doroshow JH. Morgan RJ Jr, et al. Among authors: yen y. Clin Cancer Res. 2007 Feb 15;13(4):1232-7. doi: 10.1158/1078-0432.CCR-06-1735. Clin Cancer Res. 2007. PMID: 17317834 Clinical Trial.
1,678 results